Post-TNFalpha
| Zeile 2: | Zeile 2: | ||
{{tp|p=32382744|t=2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.|pdf=|usr=008}} | {{tp|p=32382744|t=2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.|pdf=|usr=008}} | ||
{{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}} | {{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}} | ||
| + | {{tp|p=32436460|t=2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.|pdf=|usr=009}} | ||
| + | {{tp|p=32554621|t=2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.|pdf=|usr=010}} | ||
| + | |||
| + | {{tp|p=32553760|t=2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.|pdf=|usr=010}} | ||
Version vom 8. Juli 2020, 09:24 Uhr
32278362 2020. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
32382744 2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.
32473011 2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.
32436460 2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.
32554621 2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.
32553760 2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.
